Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment
Frank Bridoux(Université de Poitiers), Jean Paul Fermand(Université Paris Cité), Nianhang Chen, Éstelle Desport(Centre Hospitalier Universitaire de Poitiers), Bertrand Arnulf(Université Paris Cité), Stéphane Moreau(Université de Sherbrooke), Julie Abraham(Centre Hospitalier Universitaire de Limoges), Éric Moumas(Inserm), Arnaud Jaccard(Centre Hospitalier Universitaire de Limoges)
Cited by 27
Related Papers
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
|Kidney International|2021|2.5k
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
|American Journal of Hematology|2005|1.4k
New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
|Journal of Clinical Oncology|2012|965
Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases
|Kidney International|2021|809
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
|New England Journal of Medicine|2023|695